The vasodilatory β-blockers in the treatment of hypertension – nebivolol as an example Review article
Article Sidebar
Published:
Dec 31, 2014
Keywords:
hypertension, nitric oxide, vasodilation, nebivolol
Main Article Content
Abstract
In the treatment of hypertension we have five main groups of drugs: β-blockers, calcium antagonists, angiotensin converting enzyme inhibitors, angiotensin receptor blockers and diuretics. In each of these groups, there are at least a few molecules that despite similar primary mechanism of action differ from one another in terms of additional properties. Additional features allow to personalize antihypertensive therapy based on the patient’s profile. In the case of β-blockers, the molecule with additional properties is nebivolol. Although the drug reduces blood pressure in a similar extent as conventional β-blockers and other antihypertensive drugs, it has additional action – nitric oxide mediated vasodilatation.
Article Details
How to Cite
Balsam , P., & Grabowski , M. (2014). The vasodilatory β-blockers in the treatment of hypertension – nebivolol as an example. Medycyna Faktow (J EBM), 7(4(25), 85-91. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2344
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Van Nueten L., De Cree J.: Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovascular drugs and therapy 1998; 12(4): 339-44.
2. Toblli J.E., DiGennaro F., Giani J.F. et al.: Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular health and risk management. 2012; 8: 151-60.
3. Van de Water A., Janssens W., Van Neuten J. et al.: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. Journal of cardiovascular pharmacology 1988; 11(5): 552-63.
4. Sorrentino S.A., Doerries C., Manes C. et al.: Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade. Journal of the American College of Cardiology 2011; 57(5): 601-11.
5. McEniery C.M., Schmitt M., Qasem A. et al.: Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44(3): 305-10.
6. Makolkin V.I., Akhmedova O.O., Buval’tsev V.I. et al. [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. Kardiologiia 2003; 43(2): 40-3.
7. Rizos E., Bairaktari E., Kostoula A. et al.: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. Journal of cardiovascular pharmacology and therapeutics 2003; 8(2): 127-34.
8. Agabiti Rosei E., Rizzoni D.: Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67(8): 1097-107.
9. Marazzi G., Volterrani M., Caminiti G. et al.: Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Advances in therapy 2010; 27(9): 655-64.
10. Cleophas T.J., Agrawal R., Lichtenthal A. et al.: Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. American journal of therapeutics 2006; 13(3): 192-7.
11. Mazza A., Gil-Extremera B., Maldonato A. et al.: Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood pressure 2002; 11(3): 182-8.
12. Grassi G., Trevano F.Q., Facchini A. et al.: Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood pressure Supplement 2003; 2: 35-40.
13. Munzel T., Gori T.: Nebivolol: the somewhat-different beta-adrenergic receptor blocker. Journal of the American College of Cardiology 2009; 54(16): 1491-9.
14. Ambrosioni E., Bacchelli S., Esposti D.D. et al.: Beta-blockade in hypertension and congestive heart failure. Journal of cardiovascular pharmacology 2001; 38(Suppl. 3): S25-31.
15. Van Bortel L.M., Fici F., Mascagni F.: Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. American journal of cardiovascular drugs: drugs, devices, and other interventions 2008; 8(1): 35-44.
16. Czuriga I., Riecansky I., Bodnar J. et al.: Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular drugs and therapy 2003; 17(3): 257-63.
17. Poirier L., Cleroux J., Nadeau A. et al.: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. Journal of hypertension 2001; 19(8): 1429-35.
18. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of hypertension 2013; 31(10): 1925-38.
19. Levine H.J.: Rest heart rate and life expectancy. Journal of the American College of Cardiology 1997; 30(4): 1104-6.
20. Kasprzak J.D., Stepinska J., Wozakowska Kaplon B. et al. [Optimum heart rate – the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy]. Kardiologia polska 2012; 70(10): 1081-94.
21. Filipiak K., Tykarski A., Czarnecka D. et al.: Miejsce wazodylatacyjnych leków beta-adrenolitycznych w terapii nadciśnienia tętniczego i jego powikłań sercowo-naczyniowych. Stanowisko ekspertów. Nadciśnienie tętnicze 2010: 13.
22. Flather M.D., Shibata M.C., Coats A.J. et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European heart journal 2005; 26(3): 215-25.
23. Ghio S., Magrini G., Serio A. et al.: Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European heart journal 2006; 27(5): 562-8.
24. Dobre D., van Veldhuisen D.J., Mordenti G. et al.: Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. American heart journal 2007; 154(1): 109-15.
25. Gao Y.S., Nagao T., Bond R.A. et al.: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. Journal of cardiovascular pharmacology 1991; 17(6): 964-9.
26. Wilkinson I.B., MacCallum H., Flint L. et al.: The influence of heart rate on augmentation index and central arterial pressure in humans. The Journal of physiology 2000; 525 Pt 1: 263-70.
27. Morgan T., Lauri J., Bertram D. et al.: Effect of different antihypertensive drug classes on central aortic pressure. American journal of hypertension 2004; 17(2): 118-23.
28. London G.M., Asmar R.G., O’Rourke M.F. et al., RP investigators: Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. Journal of the American College of Cardiology 2004; 43(1): 92-9.
29. Williams B., Lacy P.S., Thom S.M. et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-25.
30. Agabiti-Rosei E., Porteri E., Rizzoni D.: Arterial stiffness, hypertension, and rational use of nebivolol. Vascular health and risk management 2009; 5(1): 353-60.
31. Dhakam Z., Yasmin, McEniery C.M. et al.: Comparison of atenolol and nebivolol in isolated systolic hypertension. Journal of hypertension 2008; 26(2): 351-6.
32. Mahmud A., Feely J.: Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. American journal of hypertension 2008; 21(6): 663-7.
33. Kampus P., Serg M., Kals J. et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57(6): 1122-8.
34. Jabbour A., Macdonald P.S., Keogh A.M. et al.: Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. Journal of the American College of Cardiology 2010; 55(17): 1780-7.
35. Studinger P., Tabak A.G., Chen C.H. et al.: The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. Journal of clinical hypertension 2013; 15(12): 910-7.
36. Stoschitzky K., Stoschitzky G., Brussee H. et al.: Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006; 106(4): 199-206.
37. Yilmaz M.B., Erdem A., Yalta K. et al.: Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol. Advances in therapy 2008; 25(9): 871-83.
38. Cordero A., Bertomeu-Martinez V., Mazon P. et al.: Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovascular therapeutics 2010; 28(1): 15-22.
39. Van Bortel L.M., Bulpitt C.J., Fici F.: Quality of life and antihypertensive effect with nebivolol and losartan. American journal of hypertension 2005; 18(8): 1060-6.
2. Toblli J.E., DiGennaro F., Giani J.F. et al.: Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular health and risk management. 2012; 8: 151-60.
3. Van de Water A., Janssens W., Van Neuten J. et al.: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. Journal of cardiovascular pharmacology 1988; 11(5): 552-63.
4. Sorrentino S.A., Doerries C., Manes C. et al.: Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade. Journal of the American College of Cardiology 2011; 57(5): 601-11.
5. McEniery C.M., Schmitt M., Qasem A. et al.: Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44(3): 305-10.
6. Makolkin V.I., Akhmedova O.O., Buval’tsev V.I. et al. [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. Kardiologiia 2003; 43(2): 40-3.
7. Rizos E., Bairaktari E., Kostoula A. et al.: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. Journal of cardiovascular pharmacology and therapeutics 2003; 8(2): 127-34.
8. Agabiti Rosei E., Rizzoni D.: Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67(8): 1097-107.
9. Marazzi G., Volterrani M., Caminiti G. et al.: Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Advances in therapy 2010; 27(9): 655-64.
10. Cleophas T.J., Agrawal R., Lichtenthal A. et al.: Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients. American journal of therapeutics 2006; 13(3): 192-7.
11. Mazza A., Gil-Extremera B., Maldonato A. et al.: Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood pressure 2002; 11(3): 182-8.
12. Grassi G., Trevano F.Q., Facchini A. et al.: Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood pressure Supplement 2003; 2: 35-40.
13. Munzel T., Gori T.: Nebivolol: the somewhat-different beta-adrenergic receptor blocker. Journal of the American College of Cardiology 2009; 54(16): 1491-9.
14. Ambrosioni E., Bacchelli S., Esposti D.D. et al.: Beta-blockade in hypertension and congestive heart failure. Journal of cardiovascular pharmacology 2001; 38(Suppl. 3): S25-31.
15. Van Bortel L.M., Fici F., Mascagni F.: Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. American journal of cardiovascular drugs: drugs, devices, and other interventions 2008; 8(1): 35-44.
16. Czuriga I., Riecansky I., Bodnar J. et al.: Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovascular drugs and therapy 2003; 17(3): 257-63.
17. Poirier L., Cleroux J., Nadeau A. et al.: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. Journal of hypertension 2001; 19(8): 1429-35.
18. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of hypertension 2013; 31(10): 1925-38.
19. Levine H.J.: Rest heart rate and life expectancy. Journal of the American College of Cardiology 1997; 30(4): 1104-6.
20. Kasprzak J.D., Stepinska J., Wozakowska Kaplon B. et al. [Optimum heart rate – the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy]. Kardiologia polska 2012; 70(10): 1081-94.
21. Filipiak K., Tykarski A., Czarnecka D. et al.: Miejsce wazodylatacyjnych leków beta-adrenolitycznych w terapii nadciśnienia tętniczego i jego powikłań sercowo-naczyniowych. Stanowisko ekspertów. Nadciśnienie tętnicze 2010: 13.
22. Flather M.D., Shibata M.C., Coats A.J. et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European heart journal 2005; 26(3): 215-25.
23. Ghio S., Magrini G., Serio A. et al.: Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European heart journal 2006; 27(5): 562-8.
24. Dobre D., van Veldhuisen D.J., Mordenti G. et al.: Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. American heart journal 2007; 154(1): 109-15.
25. Gao Y.S., Nagao T., Bond R.A. et al.: Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. Journal of cardiovascular pharmacology 1991; 17(6): 964-9.
26. Wilkinson I.B., MacCallum H., Flint L. et al.: The influence of heart rate on augmentation index and central arterial pressure in humans. The Journal of physiology 2000; 525 Pt 1: 263-70.
27. Morgan T., Lauri J., Bertram D. et al.: Effect of different antihypertensive drug classes on central aortic pressure. American journal of hypertension 2004; 17(2): 118-23.
28. London G.M., Asmar R.G., O’Rourke M.F. et al., RP investigators: Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. Journal of the American College of Cardiology 2004; 43(1): 92-9.
29. Williams B., Lacy P.S., Thom S.M. et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-25.
30. Agabiti-Rosei E., Porteri E., Rizzoni D.: Arterial stiffness, hypertension, and rational use of nebivolol. Vascular health and risk management 2009; 5(1): 353-60.
31. Dhakam Z., Yasmin, McEniery C.M. et al.: Comparison of atenolol and nebivolol in isolated systolic hypertension. Journal of hypertension 2008; 26(2): 351-6.
32. Mahmud A., Feely J.: Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. American journal of hypertension 2008; 21(6): 663-7.
33. Kampus P., Serg M., Kals J. et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57(6): 1122-8.
34. Jabbour A., Macdonald P.S., Keogh A.M. et al.: Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. Journal of the American College of Cardiology 2010; 55(17): 1780-7.
35. Studinger P., Tabak A.G., Chen C.H. et al.: The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. Journal of clinical hypertension 2013; 15(12): 910-7.
36. Stoschitzky K., Stoschitzky G., Brussee H. et al.: Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006; 106(4): 199-206.
37. Yilmaz M.B., Erdem A., Yalta K. et al.: Impact of beta-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol. Advances in therapy 2008; 25(9): 871-83.
38. Cordero A., Bertomeu-Martinez V., Mazon P. et al.: Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovascular therapeutics 2010; 28(1): 15-22.
39. Van Bortel L.M., Bulpitt C.J., Fici F.: Quality of life and antihypertensive effect with nebivolol and losartan. American journal of hypertension 2005; 18(8): 1060-6.